Fengmin Zhou

发表

Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage.

A. Klein-Szanto, G. Kruh, J. Gallo, 2007, Cancer research.

Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors.

G. Kruh, J. Gallo, Fengmin Zhou, 2010, Neuro-oncology.

CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.

Yi-hong Wang, D. King, G. Yarranton, 2003, Cancer research.

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation

Weiguo Qing, C. Reimer, C. D’Cruz, 2016, Oncotarget.

Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry.

Ping Guo, J. Gallo, Fengmin Zhou, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models

Weiguo Qing, Fengmin Zhou, W. Su, 2015, Molecular oncology.

Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.

Weiguo Qing, Jian-ming Zheng, Yunxin Chen, 2017, Oncotarget.

Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway

P. Cui, Chun-you Wang, Fengmin Zhou, 2014, BMC Cancer.

Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.

Weiguo Qing, Y. Sai, Yumin Cui, 2014, Journal of medicinal chemistry.

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy

Weiguo Qing, Meifang Zhang, Y. Sai, 2014, Cancer biology & therapy.

Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors

P. Vicini, J. Gallo, S. Pulfer, 2004, Clinical Cancer Research.

A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets

Shiqing Li, Fengmin Zhou, Xiaojie Ang, 2021, Translational cancer research.

CD 10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004 Na and Novel Analogues : Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD 10 Tumors

Yi-hong Wang, D. King, G. Yarranton, 2003 .

Abstract 5555: Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers

Donghai Li, X. Ye, Tao Chen, 2018, Clinical Research (Excluding Clinical Trials).

Abstract 3114: Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC

Weiguo Qing, C. D’Cruz, M. Frigault, 2014 .